Edgard Wehbe, MD
Nephrology · Wichita, KSNPI 1851513287
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $44,327 of the $48,986 with a category attached, or 90.5%. Bayer accounts for 67.2% of it on its own, with 28 other manufacturers making up the rest. Reporting peaked in 2022 at $29,758 and has fallen 97.9% since, to $625 in 2025. Among nephrology clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 203 payments — averaging $241.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$33K
- Vifor Pharma, Inc.$13K
- Amgen$408
- Mallinckrodt Enterprises LLC$275
- OPKO Pharmaceuticals, LLC$241
- Novartis$209
- plus $2K from 23 others
Across 2 payments — averaging $5049.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alnylam Pharmaceuticals Inc.$10K
What the payments were for
- Consulting fees$2721%
- Speaking & faculty fees$44,32790%
- Food & beverage$4,2889%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 36 | $32,902 |
| Vifor Pharma, Inc. | 22 | $12,912 |
| Amgen(2 entities) | 19 | $408 |
| Mallinckrodt Enterprises LLC | 5 | $275 |
| OPKO Pharmaceuticals, LLC | 16 | $241 |
| Novartis | 9 | $209 |
| Akebia Therapeutics Inc | 9 | $206 |
| Boehringer Ingelheim | 10 | $199 |
| AstraZeneca(2 entities) | 12 | $183 |
| Calliditas Therapeutics US Inc. | 8 | $171 |
| GSK | 8 | $148 |
| Medtronic | 1 | $123 |
| Novo Nordisk | 6 | $116 |
| Mallinckrodt Hospital Products Inc. | 6 | $110 |
| Scpharmaceuticals Inc. | 1 | $105 |
| Ardelyx, Inc. | 6 | $105 |
| Shield Therapeutics Inc | 1 | $86 |
| Shire North American Group Inc | 4 | $73 |
| Fresenius USA Marketing, Inc. | 4 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $53 |
| Travere Therapeutics, Inc. | 4 | $50 |
| Pharmacosmos Therapeutics Inc. | 2 | $43 |
| Daiichi Sankyo Inc. | 3 | $42 |
| Sanofi | 2 | $39 |
| Otsuka America Pharmaceutical, Inc. | 2 | $36 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Aurinia Pharma U.S., Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$48,986 in reported general payments places this provider in the 95th percentile of 55 nephrology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 82 | $64,780 |
| FarxigaDapagliflozin Propanediol | 41 | $50,316 |
| KerendiaFinerenone | 32 | $25,171 |
| VeltassaPatiromer Calcium Sorbitex | 18 | $18,156 |
| Sevelamer Carbonate | 68 | $12,947 |
| EliquisApixaban | 12 | $7,015 |
| Clonidine | 54 | $5,332 |
| Bumetanide | 71 | $4,100 |
| Losartan Potassium | 469 | $3,513 |
| Calcium Acetate | 35 | $2,839 |
| Furosemide | 341 | $1,990 |
| Amlodipine Besylate | 348 | $1,948 |
| Mycophenolate Mofetil | 22 | $1,795 |
| Tacrolimus | 11 | $1,724 |
| Lisinopril | 245 | $1,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $199 | $64,78082 claims |
| AstraZenecaFarxiga | $183 | $50,31641 claims |
| BayerKerendia | $32,902 | $25,17132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 55 nephrology providers in Kansas.
Other nephrology in Wichita
- Dennis RossWichita$12K
- Mohamad SandidWichita$6K
- Jany MoussaWichita$4K
- Amanda ValliantWichita$3K
- Ushasri ChallaWichita$3K
- Joseph MeouchyWichita$2K
- Michael GrantWichita$2K
- Lisa WeberWichita$2K
- Levi ShortWichita$1K
- Kenneth KovachWichita$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.